Arcus Bio - RCUS Net earnings per share for the last four quarters

Does the robotization of molecule screening and AI bioinformatics help optimize costs? The history of EPS YoY (ttm) percentage growth provides the answer, where the -6.20 level captures the current state. Simultaneously, Arcus Biosciences, Inc. (RCUS) is implementing eco-friendly reagent disposal and green logistics. R&D funding currently relies on partnership payments while the primary drugs undergo clinical trials.
RCUS (Arcus Biosciences): analytical breakdowns and indicator data

Year-over-year EPS growth (TTM) measures the trend of net income per share over a rolling year, determining the efficiency of business capitalization and its resilience to inflation. By analyzing historical year-over-year EPS growth (TTM), an investor can assess the impact of clinical trial failure risks and the dependence of Arcus Biosciences, Inc. (RCUS) on external financing on the company's actual profitability.